小儿肺动脉高压的生物标志物：挑战与建议
Biomarkers for pediatric pulmonary arterial hypertension: challenges and recommendations.
作者信息
Lohani Ozus, Colvin Kelley L, Yeager Michael E
机构信息
Department of Bioengineering, University of Colorado Denver; Department of Pediatrics-Critical Care.
Department of Bioengineering, University of Colorado Denver; Department of Pediatrics-Critical Care; Cardiovascular Pulmonary Research, University of Colorado Denver; Linda Crnic Institute for Down Syndrome, Denver, Colorado.
出版信息
Paediatr Respir Rev. 2015 Sep;16(4):225-31. doi: 10.1016/j.prrv.2015.05.003. Epub 2015 May 12.
Pediatric pulmonary arterial hypertension (PAH) is an uncommon disease that can occur in neonates, infants, and children, and is associated with high morbidity and mortality. Despite advances in treatment strategies over the last two decades, the underlying structural and functional changes to the pulmonary arterial circulation are progressive and lead eventually to right heart failure. The management of PAH in children is complex due not only to the developmental aspects but also because most evidence-based practices derive from adult PAH studies. As such, the pediatric clinician would be greatly aided by specific characteristics (biomarkers) objectively measured in children with PAH to determine appropriate clinical management. This review highlights the current state of biomarkers in pediatric PAH and looks forward to potential biomarkers, and makes several recommendations for their use and interpretation.
小儿肺动脉高压（PAH）是一种罕见疾病，可发生于新生儿、婴儿和儿童，且发病率和死亡率较高。尽管在过去二十年中治疗策略有所进步，但肺动脉循环的潜在结构和功能变化仍在进展，最终导致右心衰竭。儿童PAH的管理很复杂，不仅因为发育方面的因素，还因为大多数循证实践源于成人PAH研究。因此，客观测量PAH患儿的特定特征（生物标志物）以确定合适的临床管理，将极大地帮助儿科临床医生。本综述强调了小儿PAH生物标志物的现状，展望了潜在的生物标志物，并对其使用和解读提出了若干建议。
Zotero 插件